Artículo especial por el Día Mundial del Riñón: Las sociedades científicas españolas ante la guía ESC 2021 de prevención de la enfermedad vascular: generalizar la medida de la albuminuria para identificar el riesgo vascular y prevenir la enfermedad vascular

Instituto Nacional de Estadística (INE.) Defunciones según la causa de muerte, año 2021 (datos definitivos) y primer semestre de 2022 (datos provisionales) [consultado el 26 de diciembre de 2022]. Disponible en: https://www.ine.es/prensa/edcm_2021.pdf Visseren, 2021, 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice [corrección publicada en Eur Heart J. 2022 Nov 7;43(42):4468], Eur Heart J., 42, 3227, 10.1093/eurheartj/ehab484 Brotons, 2022, Comentario del CEIPV a las nuevas guías europeas de prevención cardiovascular 2021, Nefrologia., 10.1016/j.nefro.2022.05.003 Ortiz, 2022, ERA Council. Chronic kidney disease as cardiovascular risk factor in routine clinical practice: A position statement by the Council of the European Renal Association, Nephrol Dial Transplant, gfac257 Ortiz, 2022, ERA Council. Chronic kidney disease as cardiovascular risk factor in routine clinical practice: A position statement by the Council of the European Renal Association, Eur J Prev Cardiol, 29, 2211, 10.1093/eurjpc/zwac186 Perez-Gomez, 2019, Clarifying the concept of chronic kidney disease for non-nephrologists, Clin Kidney J., 12, 258, 10.1093/ckj/sfz007 Kidney disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1-150. Bosi, 2021, Use of nephrotoxic medications in adults with chronic kidney disease in Swedish and US routine care, Clin Kidney J., 15, 442, 10.1093/ckj/sfab210 Carriazo, 2021, More on the invisibility of chronic kidney disease… and counting, Clin Kidney J., 15, 388, 10.1093/ckj/sfab240 Lyon, 2022, Eur Heart J., 43, 4229, 10.1093/eurheartj/ehac244 Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists’ Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: Collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022;400(10365):1788-1801. Mark, 2022, Implementation, not hesitation, for SGLT2 inhibition as foundational therapy for chronic kidney disease, Lancet., 400, 1745, 10.1016/S0140-6736(22)02164-X Heerspink, 2020, Dapagliflozin in Patients with Chronic Kidney Disease, N Engl J Med., 383, 1436, 10.1056/NEJMoa2024816 EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney Disease. N Engl J Med. 2022; 10.1056/NEJMoa2204233. doi:10.1056/NEJMoa2204233. AIRG-E, EKPF, ALCER, FRIAT, REDINREN, RICORS2040, SENEFRO; SET, ONT. CKD: The burden of disease invisible to research funders. Nefrologia. 2022;42(1):65-84. Stack, 2017, Common measures of chronic kidney disease improve vascular risk prediction, Lancet Diabetes Endocrinol, 5, 675, 10.1016/S2213-8587(17)30256-5